Our Recommendations
New Publications
- Target product profile for a gambiense human African trypanosomiasis high-throughput test for verification of elimination (2022)
- Trypanosomiase humaine africaine/ Human African Trypanosomiasis (2002)
- Human African trypanosomiasis (sleeping sickness) Cinical Guidelines (2025)
- Target product profile for a gambiense human African trypanosomiasis individual test to assess infection in low prevalence settings (2022)
- PICO questions, EtD tables, GDG recommendations (2024)
Filter
17
Featured
Recommendations
1
Language
Document type
Manuals
6
Studies & Reports
4
Guidelines
4
Resource Platforms
2
Brochures
1
Countries / Regions
Africa
4
West and Central Africa
2
East and Southern Africa
2
Congo, Democratic Republic of
1
Middle East and North Africa
1
Southern Africa
1
Angola
1
South Sudan
1
Authors & Publishers
Publication Years
Category
Pharmacy & Technologies
4
Clinical Guidelines
2
DPDx Laboratory Identification of Parasites of Public Health Concerns
Including Life cycle
Chapter in Clinical guidelines -Diagnosis and Treatment manual
The present guidelines incorporate all these changes, leading to a substantial reconfiguration of therapeutic choices for both disease forms.
HAT is a serious, life-threatening disease and the efficacy of fexinidazole depends on swallowing the medicine after an appropriate intake of food as well as...
Guidelines for the treatment of human African trypanosomiasis. Web Annex A. Commissioned by WHO Cochrane Response
WHO Guidelines for the Treatment of Human African Trypanosomiasis. Web Annex B
The development of this target product profile (TPP) was led by the WHO Department of Control of Neglected Tropical Diseases (NTD) following standard WHO guidance for TPP development. In order to identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical Advisory Group (DTAG) was form...
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge...
DNDi is now striving to make fexinidazole available to the majority of people who have T.b. gambiense sleeping sickness. We are supporting a three-year access and pharmacovigilance study that began in 2020 and have so far carried out in-country training of relevant staff in 250 hospitals and...
HAT diagnosis relies on laboratory techniques because clinical signs and symptoms are unspecific. Serodiagnostic tests exist only for Tbg and are based on the detection of specific antibodies, thus they are not confirmatory of infection. With the current low disease prevalence, the positive predicti...
HAT diagnosis relies on laboratory techniques because clinical signs and symptoms are unspecific. Serodiagnostic tests exist only for Tbg and are based on the detection of specific antibodies, thus they are not confirmatory of infection. With the current low disease prevalence, the positive predicti...
Full Perscribing information on Fexinidazole Tablet for oral use
INDICATIONS AND USAGE
Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in pati...
The development of this target product profile (TPP) was led by the WHO Department of Control of Ne-
glected Tropical Diseases (NTD) following standard WHO guidance for TPP development. In order to
identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical Advisory Group (DTAG)
was...
The twentieth century ended with human African trypanosomiasis (HAT) epidemics raging across many parts of Africa. Resistance to existing drugs was emerging, and many programs aiming to contain the disease had ground to a halt, given previous success against HAT and the competing priorities associat...
Les progrès remarquables réalisés dans la lutte contre la forme à T. b. gambiense reposent sur le dépistage et le traitement curatif, une stratégie qui interrompt la transmission en réduisant le réservoir de parasites chez l’être humain. Parfois, cette
approche a été combinée avec des...
Arsenical monotherapies were previously very successful for treating human African trypanosomiasis (HAT).
Melarsoprol resistance emerged as early as the 1970s and was widespread by the late 1990s.
Melarsoprol resistance represents the only example of widespread drug resistance in HAT patients wher...
This was a Phase 3, multi-center, randomized, open-label, parallel-group, active control study where 273 male and female patients with first stage Trypanosoma brucei gambiense HAT were treated at six sites: one trypanosomiasis reference center in Angola, one hospital in South Sudan, and four hospita...
UN GUIDE POUR L’APPROVISIONNEMENTEN MÉDICAMENTS/ A guide for drug supply
Bochure in English and French
